Questions? Call 1.877.386.0206 or
Watching a family member skip doses or go without medication because of cost is one of the most stressful things a caregiver can face — but real help exists at every level, from emergency prescription programs to ongoing federal subsidies designed specifically for low-income patients. Knowing which programs fit your loved one’s situation can mean the difference between a manageable monthly bill and a dangerous gap in treatment.
Yes — state legislation can meaningfully reduce prescription drug costs, and recent state and federal actions in 2025 and 2026 are already delivering real savings for millions of Americans. But how much states can do has real limits, which is why knowing all your options matters just as much as following the latest legislative news.
States hold more sway over your pharmacy bill than most people realize. As of April 2025, approximately 23 states had passed drug price transparency laws, and 12 states had established Prescription Drug Affordability Boards (PDABs) — regulatory bodies with authority to review the cost of specific medications and set upper payment limits on what residents pay. States like Minnesota, Colorado, and Maryland are actively using these boards to prevent runaway price hikes on high-cost medications.
States can also pass bills that regulate pharmacy benefit managers (PBMs) — the powerful middlemen who negotiate drug prices between manufacturers and insurers. More than 30 states introduced legislation in recent years to counteract restrictions on the federal 340B Drug Pricing Program, with eight states successfully passing laws that expand access to deeply discounted drugs for underserved populations.
PBMs have long been criticized for driving up costs by favoring high-priced drugs that generate larger rebates for themselves. States are fighting back. Arkansas passed House Bill 1150 — the first state law in the country to ban PBM ownership of pharmacies, targeting a significant conflict of interest — though its enforcement is currently paused due to a legal challenge. This highlights an important reality: can a state drug pricing bill be overturned? Yes. State laws can face federal preemption arguments or industry lawsuits that delay or block enforcement. But even when litigation slows progress, these laws shift the policy landscape and create pressure for broader reform.
Nine states now have PDABs actively reviewing drug costs. Minnesota recently expanded its PDAB authority to set upper payment limits on high-cost drugs, and it is using prices negotiated under the federal Inflation Reduction Act as a benchmark ceiling. These boards give states a structural tool to directly cap what residents pay — a significant power that didn’t exist just a decade ago.
Twenty-three states now require drug manufacturers, PBMs, or insurers to publicly report pricing data, making it much harder for the industry to raise prices quietly. Transparency requirements create public accountability and feed critical data into affordability reviews — and they’ve already helped expose price hikes that previously went unnoticed.
Federal legislation has added serious momentum. In February 2026, Congress enacted the Consolidated Appropriations Act, 2026 (H.R. 7148), bringing sweeping PBM reform at the national level. Starting in 2028, PBMs in Medicare Part D will be compensated only through flat, fixed service fees — not through percentages of a drug’s list price. This directly removes the financial incentive to steer patients toward expensive drugs over affordable alternatives. The law also requires PBMs to pass 100% of rebates to employer health plans, which should reduce out-of-pocket costs for covered workers.
Separately, the first set of Medicare-negotiated drug prices under the Inflation Reduction Act took effect in 2026, covering 10 high-cost medications at prices that are a minimum of 38% below their 2023 list prices. These negotiations are estimated to save Medicare beneficiaries $1.5 billion annually in out-of-pocket costs. In 2027, 15 more drugs — including Ozempic and other blockbuster diabetes medications — will be added to the negotiated pricing list.
It’s a frustrating but important reality. When a bill stalls in Congress and doesn’t get voted through, it dies. Legislation that fails to pass before the end of a congressional session expires and must be reintroduced from scratch in the next session. The Prescription Drug Price Relief Act of 2025, for example, was introduced to aggressively benchmark U.S. drug prices against international rates but had not passed as of early 2026. When federal bills stall or fail, states often step in — which is exactly the pattern we’ve seen with the surge in state PBM and affordability laws over the past two years.
It’s also worth clarifying the boundaries of state power. States cannot recall a sitting U.S. congressman — federal recall of members of Congress is not permitted under the Constitution. States also have very limited authority over federal electoral processes once set in motion. State drug pricing power, while meaningful and growing, always operates within the boundaries of federal law.
For most Americans — especially those without insurance or with high deductibles — the practical impact of new legislation is still catching up with what patients face at the pharmacy counter today. With over 350 brand-name drugs seeing price hikes in 2026, the financial burden hasn’t disappeared despite policy progress. PBM compensation reforms won’t fully take effect until 2028. PDAB upper payment limits are still being developed in most states. And Medicare drug negotiations benefit Medicare enrollees specifically — they don’t automatically lower prices for the uninsured or privately insured.
If you’re struggling to afford your medications today, waiting for the next legislative session is not a plan. That’s where prescription assistance programs become essential.
Simplefill’s patient assistance program connects uninsured and underinsured Americans with pharmaceutical company programs, state-sponsored initiatives, and other funding sources that can provide brand-name and specialty drugs at little to no cost — completely independent of whatever is happening in any state legislature.
For additional tools you can use right now alongside any policy changes, explore 10 ways to lower your prescription costs — a practical guide to maximizing every available savings option no matter your insurance status.
Simplefill is a full-service prescription assistance company that maintains patients’ enrollment in all sources of assistance available to them.
Apply today by calling 877-386-0206. A representative will contact you within 24 hours.
Yes. States can regulate PBMs, establish drug affordability boards with power to set upper payment limits, pass price transparency laws, and expand access to 340B discounted drug pricing — all without waiting for federal action.
It expires at the end of the congressional session and must be reintroduced. States often fill the gap with their own legislation, which is why state-level PBM and affordability laws have surged in recent years.
Yes. State laws can be challenged in court on federal preemption grounds, or blocked by industry litigation. Arkansas’s PBM pharmacy ownership ban is a recent example — it passed but is currently under a legal enforcement pause.
The negotiated prices apply specifically to Medicare Part D and Part B enrollees. However, some states — like Minnesota — are already using these prices as reference benchmarks for their own upper payment limits, which could eventually broaden the impact.
Simplefill goes beyond coupons by enrolling you in pharmaceutical patient assistance programs that can provide medications free or at near-zero cost. Simplefill also monitors your refills, manages renewals, and advocates for you continuously — ongoing support that a discount card simply doesn’t offer.
You still have options. Federal PBM reforms, Medicare drug negotiations, and manufacturer patient assistance programs are available to eligible patients nationwide. Simplefill can identify and enroll you in every program you qualify for, regardless of your state
TrumpRx is available right now and delivering real discounts to a specific slice of the population — but the Great Healthcare Plan is a legislative framework that hasn’t passed Congress yet and may be a year or more away from changing what you actually pay. If you’re uninsured or paying out of pocket for expensive medications today, understanding which initiative actually helps you — and on what timeline — matters more than the headlines.
TrumpRx launched on February 5, 2026 as a federal government website at TrumpRx.gov. It doesn’t sell medications directly — instead, it functions as a portal that directs patients to pharmaceutical manufacturers’ websites where they can purchase specific drugs at pre-negotiated cash prices significantly below the standard retail list price.
The platform launched with discounts on 40 of the most expensive and commonly prescribed brand-name drugs in the country. Some of the price reductions are genuinely dramatic:
Ozempic (semaglutide injectable): dropped from $1,028/month to as low as $199 depending on dosage
Wegovy (injectable): dropped from $1,349/month to an average of $350
Wegovy (oral pill): dropped from $1,349/month to as low as $149
Bevespi Aerosphere (COPD inhaler): dropped from $458 to $51/month
Cetrotide (fertility): dropped from $316 to $22.50
These discounts are the product of Most-Favored-Nation (MFN) pricing agreements that the Trump administration began negotiating in May 2025, eventually reaching deals with 16 major pharmaceutical manufacturers by the end of 2025.
This is the most important question to ask before getting too excited about the headlines — and the honest answer is: a specific subset of patients, not the majority.
TrumpRx is designed for cash-paying, uninsured patients and those whose medications aren’t covered by their insurance plan. If that describes your situation, the discounts are meaningful and accessible today. However, several groups are explicitly excluded or unlikely to benefit:
Medicare and Medicaid enrollees cannot use TrumpRx — participants in any government-funded prescription drug benefit are ineligible
Insured patients using their pharmacy benefits will almost always pay less through their plan than through TrumpRx cash prices — and critically, TrumpRx purchases do NOT count toward annual deductibles or out-of-pocket maximums
Patients near their out-of-pocket maximum would lose significant protection by switching to cash pay, since insurers cover 100% of costs once the cap is hit
According to STAT News analysis, TrumpRx realistically benefits approximately 15% of Americans — those with no or marginal prescription drug coverage. For the other 85%, existing insurance benefits remain cheaper in most cases.
That said, for patients in the uninsured 15% — which includes many of Simplefill’s members — any reduction from full list price is meaningful, and TrumpRx prices are a genuine improvement over the pre-deal retail baseline. The question is whether they’re the best option available, or whether patient assistance programs can do even better.
Here’s the comparison most patients don’t know to make. Before TrumpRx existed, uninsured patients could already access many of these same brand-name medications for free — not at a discount, but at no cost at all — through manufacturer patient assistance programs (PAPs).
The New York Times noted pointedly that for individuals without any health insurance, “manufacturers provide these drugs for free or at significantly reduced rates” through existing PAP infrastructure. That dynamic didn’t change when TrumpRx launched.
The practical takeaway:
For uninsured patients who qualify for a PAP — typically those earning under certain income thresholds with a valid prescription and no government drug coverage — a free medication through Simplefill’s medication assistance program is a better financial outcome than a discounted cash price through TrumpRx. The distinction is income and eligibility: TrumpRx has no income test, while PAPs do. If you don’t qualify for a PAP, TrumpRx is a meaningful step down from full retail.
The Great Healthcare Plan is a legislative framework President Trump called on Congress to enact on January 15, 2026. It is broader in scope than TrumpRx and addresses not just drug prices but the entire structure of healthcare affordability — but it requires Congressional action to become law, which means it operates on a fundamentally different timeline than a White House website.
The plan’s core components include:
Codifying MFN pricing — making the voluntary manufacturer pricing agreements already negotiated into permanent law, locking in the discounts currently accessible through TrumpRx across all channels, not just cash pay
Restoring and restructuring ACA premium subsidies — the enhanced ACA subsidies that kept premiums affordable for marketplace enrollees expired at the end of 2025, affecting approximately 22 million people; the Great Healthcare Plan proposes to replace them and cut premiums on popular ACA plans by an average of 10–15%
Eliminating broker and middleman kickbacks — targeting the insurance broker compensation structures that Trump’s plan argues drive up premiums
Funding the Cost Sharing Reduction program — a long-underfunded ACA provision that would reduce out-of-pocket costs (not just premiums) for lower-income marketplace enrollees
Maximizing price transparency — requiring hospitals, insurers, and pharmacy benefit managers to disclose true negotiated prices
The Kaiser Family Foundation noted that the plan “leaves open key questions” including details on out-of-pocket costs, coverage for people with pre-existing conditions, and total federal spending impact.
This is where patients paying bills today need to be clear-eyed. The Great Healthcare Plan is a proposal, not a law. As of late February 2026, it has not been passed by Congress, and legislative analysts note that it is uncertain whether Congress will act on it this year at all.
Policy experts and healthcare law firms monitoring the situation describe the plan as a “framework” — a statement of intent and direction rather than an enacted set of rules patients can rely on now. Even if Congress takes up and passes the legislation quickly, the implementation of new insurance rules, premium structures, and codified drug pricing typically follows enactment by months or years of regulatory rulemaking.
The honest answer to “which will lower your costs first” is: TrumpRx already has, for uninsured cash-pay patients on the 40 covered drugs. The Great Healthcare Plan, if enacted, would eventually be far more impactful — it would benefit insured patients too, codify pricing across all purchase channels, and restore ACA coverage for millions — but “eventually” is the operative word.
Given the current landscape, here’s the practical priority order for an uninsured patient struggling to afford their medications today:
Check if you qualify for a manufacturer PAP first. If your income qualifies and you have a valid prescription, free medication through a PAP beats a discounted cash price every time. Simplefill’s prescription assistance program handles the entire research, application, and enrollment process for you.
Check TrumpRx for your specific medications. If you don’t qualify for a PAP — either because your income is above the threshold or your drug isn’t covered by one — TrumpRx cash prices are now meaningfully lower than retail list prices for the 40 drugs currently on the platform. Visit TrumpRx.gov, identify your drug, and compare the cash price to what you’re currently paying.
Don’t use TrumpRx if you’re insured and near your out-of-pocket maximum. The savings calculation changes dramatically once you factor in the loss of deductible and OOP max credit. Run the numbers with your pharmacist before switching to cash pay.
Monitor the Great Healthcare Plan’s progress — particularly the ACA subsidy restoration component if you buy marketplace insurance. If Congress acts, the premium cuts could be significant.
Ask about alternatives if your drug isn’t on TrumpRx or a PAP. Simplefill researches therapeutic alternatives that may have assistance available when your specific medication doesn’t. That option is part of every standard Simplefill enrollment.
Policy proposals don’t fill prescriptions. If you are uninsured, paying out of pocket, or paying more than you can manage for a chronic condition medication right now, the fastest path to relief isn’t TrumpRx or the Great Healthcare Plan — it’s a phone call to Simplefill.
Simplefill is a full-service prescription assistance company that maintains patients’ enrollment in all sources of assistance available to them.
Apply today by calling 877-386-0206. A representative will contact you within 24 hours.
No. TrumpRx is strictly a direct-to-consumer (DTC) platform for cash-paying patients.
The Rule: You are not eligible for TrumpRx coupons if you are enrolled in any government-funded program, including Medicare Part D, Medigap, Medicaid, the VA, or TRICARE.
The Alternative: Many Medicare and Medicaid beneficiaries are now seeing costs capped through separate federal agreements (such as the $50 monthly cap for GLP-1s) rather than through this website.
No. Purchases made through TrumpRx are considered “out-of-network” cash payments.
Important Warning: Dollars spent here do not count toward your private insurance deductible or your annual out-of-pocket maximum.
Check First: If you have a high-deductible plan and expect to hit your limit this year, using your insurance (even at a higher initial price) might save you more money in the long run than using TrumpRx.
No. As of February 24, 2026, it remains a legislative proposal.
Current Status: President Trump formally called on Congress to enact the plan on January 15, 2026.
What it aims to do: If passed, it would codify “Most-Favored-Nation” (MFN) pricing into law, eliminate PBM kickbacks, and move certain prescription drugs to over-the-counter (OTC) status. For now, the savings on TrumpRx are based on voluntary agreements with manufacturers, not new laws.
The platform launched with roughly 43 high-cost branded medications. Key categories include:
Weight Loss/Diabetes: Ozempic, Wegovy (injectable and oral), Zepbound, and Trulicity.
Respiratory: Inhalers like Airsupra, Advair Diskus, and Bevespi Aerosphere.
Fertility: Gonal-F, Cetrotide, and Ovidrel.
Other: Repatha (cholesterol), Mayzent (MS), and various insulins.
Note: TrumpRx does not sell these drugs directly; it provides coupons or links to manufacturer-owned pharmacies like LillyDirect.
Uninsured patients are still protected by the voluntary MFN agreements already signed by 16 major manufacturers (including Pfizer, Eli Lilly, and AstraZeneca). These agreements established the current TrumpRx prices and remain in effect regardless of the Congressional vote. Simplefill’s advocacy services also operate independently of any new legislation.
Employers across the country are scaling back or eliminating coverage for GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound — and if your employer is among them, your options for affording these drugs without insurance coverage are more varied than most patients realize. Understanding exactly what’s happening, why it’s happening, and what you can do about it is the first step toward protecting your access to medication you depend on.
The pullback is real, it’s accelerating, and it’s being driven almost entirely by cost. GLP-1 medications run between $617 and $766 per month at list price — and when large employers began covering them at scale, the impact on pharmacy benefit spending was immediate and significant.
The numbers tell the story clearly. In 2025, GLP-1 drugs for weight loss represented over 10% of all annual prescription drug claims among employer-provided health plans in the U.S. Among large employers with 5,000 or more employees, 66% reported that covering GLP-1s for weight loss had a “significant” impact on their prescription drug spending.
The response from many of those employers has been swift:
Blue Cross Blue Shield of Massachusetts dropped GLP-1 coverage for obesity treatment for employers with fewer than 100 employees at the start of 2026
Harvard Pilgrim Health Care and Blue Cross Blue Shield of Michigan both dropped weight-loss GLP-1 coverage in 2026
HCA Healthcare — one of the country’s largest hospital systems — notified employees that its GLP-1 coverage was ending after usage surged 90% in a single year, directing workers instead toward manufacturer cash-pay programs
Several other employers have stopped short of elimination but have tightened requirements dramatically — restricting coverage only to patients with a formal diabetes diagnosis and removing access for patients using GLP-1s for weight management alone.
The cost math simply stopped working for many plan sponsors. A study from the Employee Benefit Research Institute estimates that expanding GLP-1 coverage would drive health plan premiums up between 5% and 14%, depending on adherence and eligibility. For employers operating on tight benefit budgets, that’s an untenable increase to absorb — especially when utilization consistently came in higher than projected.
In conversations documented by the Kaiser Family Foundation and Peterson Center on Healthcare, employers described trying multiple cost-management strategies — step therapy requirements, prior authorization, weight-loss program prerequisites — before ultimately concluding that no guardrail was controlling the spend fast enough.
Importantly, the law doesn’t require employers to offer GLP-1 coverage. The federal Employee Retirement Income Security Act (ERISA) does not mandate it, and courts have largely sided with insurers on this issue — most recently on February 19, 2026, when the U.S. Court of Appeals for the First Circuit upheld Cigna’s right to exclude weight-loss drug coverage without it constituting disability discrimination.
This distinction matters enormously right now, and patients need to understand it.
Most employers that are cutting GLP-1 coverage are specifically cutting coverage for weight management indications — meaning Wegovy, Zepbound, and Saxenda prescribed for obesity. Most are retaining coverage for GLP-1s prescribed to treat Type 2 diabetes — meaning Ozempic and Mounjaro used for blood sugar control.
If you were on a GLP-1 for both diabetes and weight management and your employer drops weight-loss coverage, your prescriber may be able to document a diabetes or pre-diabetes indication that retains your coverage eligibility. This is worth discussing directly with your healthcare provider before assuming your coverage is gone.
If you were using a GLP-1 exclusively for weight management and your employer has eliminated that coverage category entirely, you are now effectively uninsured for that medication — and you need to know what assistance options exist.
Losing employer coverage for an expensive medication you depend on is stressful, but it is not the end of the road. Several assistance pathways exist, and the right one depends on your diagnosis, income, and the specific drug you’ve been prescribed.
Novo Nordisk and Eli Lilly both operate patient assistance programs (PAPs) that provide free or reduced-cost medications to qualifying patients who are uninsured or underinsured. Simplefill’s Ozempic patient assistance program page outlines exactly what’s available for semaglutide specifically, including eligibility requirements and what the application process involves. Simplefill researches and applies to these programs on your behalf — you don’t navigate the manufacturer’s paperwork alone.
Both Novo Nordisk and Eli Lilly have launched direct-to-patient platforms offering GLP-1 medications at flat cash-pay rates significantly below the insurance list price. These programs are designed specifically for patients who either lost coverage or never had it. They’re not the same as a free PAP, but they do represent a more manageable cost floor than paying $700+ out of pocket through a retail pharmacy.
In November 2025, President Trump finalized pricing agreements with Eli Lilly and Novo Nordisk that — starting in mid-2026 — will allow Medicare to cover GLP-1s for obesity for the first time, with a $50/month patient copay. The agreements also reduce the cost Medicaid programs pay for these drugs. For patients not on Medicare, these agreements set a new pricing precedent that may bring cash-pay costs down further as the year progresses.
In a development announced today (February 24, 2026), Novo Nordisk confirmed it will slash the list price of Ozempic, Wegovy, and Rybelsus by up to 50%, setting a unified price of $675 across all three products beginning January 1, 2027. While that date is still months away, it signals meaningful future relief for uninsured and cash-pay patients.
If you’ve lost employer GLP-1 coverage and aren’t sure which program you qualify for, this is exactly the scenario Simplefill’s patient assistance program is built for. An advocate reviews your income, diagnosis, insurance status, and the specific medication you’ve been prescribed — then researches and applies to every available source of assistance, including PAPs, grants, and alternative funding programs, on your behalf.
A growing number of employers are drawing a hard line: GLP-1 coverage remains in place, but only for a formal Type 2 diabetes diagnosis. For patients using these medications to manage obesity — including those who had pre-diabetes, metabolic syndrome, or significant cardiovascular risk — that restriction can feel deeply unfair, particularly if the medication was working.
There are a few things worth doing immediately if you’re in this situation:
Talk to your prescribing physician about whether your medical record documents all qualifying conditions — including pre-diabetes, cardiovascular disease, or sleep apnea — that could support a covered indication under your employer’s revised policy
Request a formal medical necessity letter from your provider if you plan to appeal your insurer’s coverage denial
Research your state’s Medicaid position on GLP-1s — Simplefill’s breakdown of the state-by-state divide over GLP-1 Medicaid coverage is an up-to-date resource on which states are covering these medications and under what conditions
The patients who get the best outcomes from prescription assistance are the ones who start the process before their coverage actually lapses. If your employer has announced a GLP-1 coverage change that takes effect in the coming weeks or months, now is the time to act — not after you’ve missed your first dose and your next refill isn’t covered.
Simplefill is a full-service prescription assistance company that maintains patients’ enrollment in all sources of assistance available to them.
Apply today by calling 877-386-0206. A representative will contact you within 24 hours.
Yes. Even if you have insurance, a “coverage gap” (where a plan explicitly excludes a medication) can make you eligible for certain types of assistance.
Manufacturer Programs: If your insurance no longer covers the drug, you are technically “uninsured” for that specific medication.
Simplefill Advocacy: Simplefill evaluates your specific plan details to see if grant assistance or a patient assistance program (PAP) can bridge the gap.
Yes. Novo Nordisk continues to operate a Patient Assistance Program (PAP) in 2026 for qualifying patients.
Eligibility: Generally requires you to be a U.S. citizen/resident and have a household income at or below 200% of the Federal Poverty Level (for Ozempic) or 400% (for other products).
Medicare Change: As of 2026, many manufacturer programs have restricted access for Medicare Part D beneficiaries, though these patients may now qualify for the new $50 monthly copay cap through federal programs.
Eligibility thresholds vary based on the medication and the type of help:
Manufacturer PAPs: Typically look for income below $31,300 (single) or $42,300 (married) for certain medications like Ozempic.
Financial Assistance Grants: Simplefill helps patients with higher incomes—sometimes up to $105,570—qualify for specific funding grants if the out-of-pocket cost is a significant burden.
Yes, specifically for cash-pay and Medicare patients. * TrumpRx Platform: Launching in early 2026, this direct-to-consumer platform offers GLP-1 injectables for approximately $350 per month, bypassing many traditional insurance hurdles.
Medicare/Medicaid: Under these landmark agreements, many government-insured patients will see monthly copays capped at $50.
On February 24, 2026, Novo Nordisk announced it will slash the list prices of Wegovy and Ozempic by up to 50%, bringing the list price down to $675 per month.
Effective Date: This change takes effect January 1, 2027.
Who it helps: This primarily benefits people with high-deductible plans or those paying coinsurance based on the “sticker price.”
If you’re uninsured and struggling to afford your medications, prescription assistance programs (PAPs) offer a legitimate path to receiving brand-name and specialty drugs at little to no cost — and Simplefill exists specifically to help you find, apply for, and stay enrolled in every program you qualify for. This guide walks you through what these programs are, who qualifies, what types of assistance are available, and how to get started today.
When the World Health Organization (WHO) labels obesity a chronic disease, it signals that excess weight isn’t just about willpower—it’s a long-term medical condition that requires ongoing care, treatment, and support. For people across the U.S. who rely on medications, counseling, or surgery to manage obesity and related conditions like diabetes or heart disease, this shift reinforces that you deserve real, sustained treatment options—not judgment.
At least 350 brand‑name medications are expected to see U.S. price hikes in 2026, including vaccines and blockbuster drugs for cancer, COVID‑19, and chronic conditions. For patients and families nationwide, those increases will pile onto already rising premiums and out‑of‑pocket costs, making access to a full‑service prescription assistance program more important than ever.
The states that will likely see the biggest savings from Medicare drug negotiations are those with the largest Medicare populations, the highest use of expensive Part D and Part B drugs, and a high share of people with chronic conditions—states like Florida, Texas, California, New York, and Pennsylvania. For people in South Carolina, especially retirees in communities like Mount Pleasant, the savings may not be the very highest in the nation, but they will still be meaningful—especially for those who rely on negotiated drugs for chronic conditions.
Medicare’s new price negotiation authority, created under the Inflation Reduction Act, allows the Centers for Medicare & Medicaid Services (CMS) to negotiate prices for a limited list of high-spend drugs each year. CMS focuses on drugs with the highest total Medicare spending, long time on the market, and no generic or biosimilar competition, which means the impact is concentrated on medications that millions of people take for chronic, high-impact conditions.
Even though negotiated prices are set nationally, the savings look different state by state because of how many people in each state actually use those drugs. States with more Medicare enrollees, higher rates of diabetes, heart disease, arthritis, cancer, and autoimmune conditions, and greater reliance on expensive brand-name medications will see larger aggregate reductions in Medicare spending and out-of-pocket costs.
When you look at overall Medicare spending, certain states stand out because of their size and demographic mix. States most likely to see the biggest total dollar savings from negotiated drug prices include:
From a patient’s perspective, that doesn’t mean people in other states are left out; it simply means the largest total savings will cluster where Medicare spending is already highest.
Because negotiated prices apply nationwide, the “which states benefit most” conversation is really about where the drugs on the negotiation list are used most heavily. States with these characteristics will tend to see larger total savings:
On the other hand, a state with fewer older adults, greater reliance on generics, or lower uptake of the negotiated drugs will see smaller aggregate savings—even though individual patients may still benefit.
Many patients are in a similar situation: they have Medicare, but they still struggle with high out-of-pocket costs for necessary medications. Negotiated prices help in several ways:
For those whose medications are not yet included in negotiations, working with a patient assistance program can unlock additional savings through manufacturer programs, grants, and other sources.
Even in the states with the largest projected savings, negotiated prices alone rarely solve every affordability problem, especially for people taking multiple brand-name medications. That’s where a full-service prescription assistance partner becomes essential.
An organization like Simplefill helps patients:
In practice, the best time to seek help is as soon as your prescription costs start to strain your budget, rather than waiting until you are deep into the year or already in a coverage gap.
Warning signs include:
A full-service prescription assistance company can review your situation, identify programs and potential savings, and handle the applications and renewals for you so you can focus on your health.
Simplefill is a full-service prescription assistance company that researches, qualifies, and maintains patients’ enrollment in all sources of assistance available to them.
Apply today by calling 877-386-0206. A caring Simplefill representative will contact you within 24 hours to discuss your application and, if qualified, enroll you in the program.
The Medicare Drug Price Negotiation Program lets Medicare negotiate prices directly with drug manufacturers for a limited list of high-spend Part D and Part B drugs, based on factors like total Medicare spending, years on the market, and lack of generic or biosimilar competition. Negotiated prices are then implemented nationally for eligible beneficiaries, with new groups of drugs added over time.
The first negotiated prices apply to an initial group of drugs and begin phasing in over the middle of this decade, with additional drugs and price changes scheduled in subsequent years. For many people with Medicare Part D, the most noticeable savings will come as negotiated prices combine with the new annual prescription drug cap to limit overall out-of-pocket spending.
No, only a select list of high-impact drugs is eligible for negotiation, and certain medicines—such as orphan drugs for very rare conditions, plasma-derived products, generics, and biosimilars—are excluded from the program. Many other prescriptions will continue to be priced through normal plan negotiations, formulary decisions, and existing manufacturer discount or prescription assistance programs.
If your drug is not yet negotiated, you may still benefit from the new Medicare prescription drug cap, plan-level discounts, or manufacturer and nonprofit patient assistance programs that reduce out-of-pocket costs. A full-service medication assistance program can help you compare options, check your plan’s formulary, and enroll in available programs so you can keep affording your medications over the long term.
Drug shortages are a serious issue throughout the country, hiking prices beyond their already difficult-to-afford rates and making it a challenge for people to receive the medications they need for conditions like cancer, heart disease, and ulcerative colitis.
In 2026, some healthcare plans are removing certain medications from their formularies. Some may not be fully removing them but could instead require prior authorization or step therapy before you can access the drugs you need. As a result, you could struggle to afford lifesaving medications for chronic conditions like asthma or HIV.
